Skip to main content
GENEDRIVE PLC logo

GENEDRIVE PLC — Investor Relations & Filings

Ticker · GDR ISIN · GB00B1VKB244 LEI · 213800ZYODIRZ87Y4K14 IL Manufacturing
Open in API
Filings indexed 606 across all filing types
Latest filing 2025-05-30 Remuneration Information
Country GB United Kingdom
Listing IL GDR

About GENEDRIVE PLC

https://genedriveplc.com/

Genedrive PLC is a molecular diagnostics company specializing in the development and commercialization of a rapid, point-of-care pharmacogenetic testing platform. The company's core technology, the Genedrive® System, is designed for the swift diagnosis of genetic variants to enable personalized medicine in critical care settings. Its key products include the Genedrive® MT-RNR1 ID Kit, used to prevent antibiotic-induced hearing loss in infants, and the Genedrive® CYP2C19 ID Kit, which helps optimize antiplatelet therapy for stroke patients. The platform empowers clinicians to make safer and more effective treatment decisions by providing crucial genetic information at the point of need, thereby improving patient outcomes.

Recent filings

Filing Released Lang Actions
Block Listing Returns
Remuneration Information Classification · 1% confidence The document explicitly states it is an 'RNS Number' filing and confirms the 'block listing six monthly return for the period to 30 May 2025'. It details the balance of unallocated securities under various share option schemes over the period from 30 November 2024 to 30 May 2025. This type of filing, which reports on the status of securities reserved for employee share schemes, is a specific regulatory disclosure often submitted to exchanges like the London Stock Exchange (LSE) via RNS. While it relates to capital/shares, its primary function here is a routine regulatory update on scheme utilization, which fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Block Listing Return'. It is not an Earnings Release (ER), Interim Report (IR), or a formal Annual Report (10-K).
2025-05-30 English
CE-certification
Regulatory Filings Classification · 1% confidence The document is identified by the RNS Number header and contains a date (30 May 2025) and company information, typical of a regulatory news service announcement. The content describes a specific corporate event: the Genedrive® CYP2C19 ID Kit receiving CE-certification under the European In Vitro Diagnostics Regulation (IVDR). This is a material announcement concerning product regulatory status and market access, which is generally disseminated via regulatory news wires. Since it is an announcement of a specific event/achievement rather than a comprehensive periodic report (like 10-K or IR) or a general call transcript, it fits best under the general Regulatory Filings category (RNS), as it is explicitly distributed via RNS and does not match any other specific category like ER, CAP, or LTR.
2025-05-30 English
CYP2C19-ID Kit used to support expansion
Regulatory Filings Classification · 1% confidence The document is a press release distributed via the London Stock Exchange's Regulatory News Service (RNS). It announces a specific commercial development regarding the use of the company's Genedrive CYP2C19-ID Kit in a clinical trial. Since it is a general regulatory announcement that does not fit into more specific categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2025-05-13 English
CYP2C19 ID Kit CE-IVD certification update
Regulatory Filings Classification · 1% confidence The document starts with 'RNS Number' and is dated May 2, 2025. It announces an update regarding the CE-IVD certification process for a product (Genedrive® CYP2C19 ID Kit), stating a delay of approximately one month. The text concludes with standard disclaimers from RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. Since this is a short, specific announcement of an operational/regulatory update that doesn't fit into major categories like 10-K, ER, or IR, and it is distributed via RNS, the most appropriate classification is the general Regulatory Filings category (RNS), as it is a miscellaneous regulatory announcement. Applying the 'MENU VS MEAL' rule: The document is short (4287 chars) and is an announcement about a certification process delay, not the full certification report itself. Therefore, RNS is the correct classification.
2025-05-02 English
Additional grant funding under DEVOTE programme
Regulatory Filings Classification · 1% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service) announcing that Genedrive PLC has been awarded additional grant funding under the DEVOTE programme. It details the nature of the funding, the partnership with the University of Manchester, and the impact on the company's product development. As this is a general corporate announcement regarding business operations and funding that does not fit into specific categories like M&A, dividends, or financial reports, it is classified as a Regulatory Filing (RNS).
2025-04-02 English
Receipt of R&D tax credit
Regulatory Filings Classification · 1% confidence The document is a short announcement (under 5,000 characters) issued via the London Stock Exchange's RNS service. It reports a specific corporate event—the receipt of an R&D tax credit—which does not fall into specialized categories like M&A, dividends, or director dealings. As it is a general regulatory announcement that does not fit into more specific categories, it is classified as a Regulatory Filing (RNS).
2025-04-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.